Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600661 | 0.94 | KDM4E (0.55) | KDM4EHSD17B10ATMGRIN2BMEN1 | |
| SCHEMBL3594735 | 0.84 | HSD17B10 (0.57) | KDM4EHSD17B10MAPTGRIN2BMEN1 | |
| SCHEMBL3597694 | 0.84 | HPGD (0.50) | KDM4EHSD17B10MAPTGRIN2BMEN1 | |
| SCHEMBL3607170 | 0.82 | KDM4E (0.51) | KDM4EHSD17B10GRIN2BKMT2ASMN1; SMN2 | |
| SCHEMBL3604427 | 0.81 | GRIN2B (0.45) | KDM4EMAPTGRIN2BKMT2AALDH1A1 | |
| SCHEMBL3605190 | 0.80 | KMT2A (0.49) | KDM4EHSD17B10MAPTGRIN2BMEN1 | |
| SCHEMBL3596487 | 0.80 | KDM4E (0.54) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3591923 | 0.80 | GRIN2B (0.44) | KDM4EHSD17B10GRIN2BKMT2ASMN1; SMN2 | |
| SCHEMBL3591928 | 0.80 | GRIN2B (0.46) | KDM4EHSD17B10GRIN2BKMT2ASMN1; SMN2 | |
| SCHEMBL3597085 | 0.80 | KDM4E (0.46) | KDM4EHSD17B10GRIN2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | KDM4E 4801/4885HSD17B10 3413/4885ATM 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.